NEW YORK (GenomeWeb) — Novacyt said today that it has partnered with Applied Microarrays (AMI) on the development of microarray-based SNP assays for diagnostic applications.
Under the terms of the deal, Novacyt's molecular testing division Primerdesign will help AMI design probes for customized SNP microarrays, which are used in point-of-care and laboratory settings. Additional terms were not disclosed.
"This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business," Novacyt CEO Graham Mullis said in a statement. "I am also pleased to see continued progress in our business-to-business opportunities converting into commercial partnerships."
Earlier this year, Primerdesign — which Novacyt acquired in 2016 — signed an agreement to develop an influenza and respiratory virus clinical assay with GenePOC. Last month, Novacyt said that its first half revenues from Primerdesign rose 15 percent amid growth in core research-use-only markets.